Friday, July 10, 2026

Drug profile · INN

bazedoxifene

bazedoxifene (CONBRIZA) is a estrogen receptor modulator.

EMA: approved Genito-urinary system and sex hormones (G03) G03XC02
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — bazedoxifene
Class
Genito-urinary system and sex hormones (G03)
Route
Patents
0
Programs
1
Data quality
0.83

Quick answer

bazedoxifene (CONBRIZA) is a estrogen receptor modulator.

Key facts

INN bazedoxifene
Brand CONBRIZA
Mechanism Estrogen receptor modulator
Therapeutic class Genito-urinary system and sex hormones (G03)
ATC code G03XC02

Mechanism of action

Estrogen receptor modulator

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. Estrogen-bazedoxifene Unknown · United Therapeutics Europe · Hand Osteoarthritis

Related & competitor drugs

  1. apomorphine Genito-urinary system and sex hormones (G04)
  2. mirabegron Genito-urinary system and sex hormones (G04)
  3. oxybutynin Genito-urinary system and sex hormones (G04)
  4. raloxifene Genito-urinary system and sex hormones (G03)
  5. sildenafil Genito-urinary system and sex hormones (G04)
  6. silodosin Genito-urinary system and sex hormones (G04)

Frequently asked questions

What is bazedoxifene?

bazedoxifene (CONBRIZA) is a estrogen receptor modulator.

What is the brand name for bazedoxifene?

CONBRIZA is a marketed brand name for bazedoxifene. Check FDA Drugs@FDA for the current US label holder and prescribing information.